Welcome to our dedicated page for CareDx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on CareDx stock.
CareDx, Inc. (NASDAQ: CDNA) is at the forefront of transforming transplant patient care through its innovative surveillance management solutions. Dedicated to improving the lives of organ transplant patients, CareDx leverages the latest in genomics and bioinformatics technology combined with rigorous clinical evidence derived from trials and registries.
CareDx offers a suite of precision medicine solutions aimed at enhancing both pre- and post-transplant care. One of its flagship products, AlloSure®, is the first and only non-invasive blood test that directly measures allograft injury. This next-generation sequencing (NGS) based test detects donor-derived cell-free DNA (dd-cfDNA), providing clinicians with a powerful tool to identify organ injury and the probability of active rejection, particularly in kidney transplant patients.
The company's portfolio also includes AlloMap Heart, AlloSure Heart, and AlloSure Lung, which are dd-cfDNA solutions designed for heart and lung transplant recipients. These products underscore CareDx’s commitment to offering clinically differentiated, high-value healthcare solutions that span the entire transplant journey.
CareDx generates the majority of its revenue from the United States, with a significant portion coming from its testing services. Its product suite not only addresses the critical needs of transplant patients but also supports healthcare providers in delivering better patient outcomes through genomics-based information.
Recent achievements include the continued expansion of their product line and partnerships with leading healthcare institutions to further validate and implement their innovative diagnostic solutions. These efforts position CareDx as a leader in the field of transplant diagnostics and surveillance.
CareDx, Inc. (Nasdaq: CDNA) announced its sponsorship of the 2022 Donate Life Transplant Games in San Diego from July 29 to August 3, 2022. The company is promoting its AlloCare mobile app, which assists transplant patients throughout their healthcare journey. The Games are expected to host over 6,000 participants, celebrating organ donors and recipients through various athletic events. CareDx aims to raise awareness for organ donation while enhancing community connectivity among transplant patients.
CareDx, Inc. (Nasdaq: CDNA) has released its inaugural environmental, social, and governance (ESG) report, highlighting its commitment to enhancing the transplant ecosystem. CEO Reg Seeto emphasized the importance of integrating ESG principles into their operations to improve patient outcomes. Key accomplishments include investments in transplant research and digital health solutions, support for minority organ donations through partnerships, and initiatives like RemoTraC™, which facilitates at-home testing for transplant patients. The report reflects CareDx's ongoing dedication to accountability and healthcare equity.
CareDx, Inc. (Nasdaq: CDNA), a leader in precision medicine for transplant patients, will participate in the Jefferies Healthcare Conference on June 9, 2022, at 2:00 PM ET. The presentation can be accessed via the investor relations section of CareDx's website. CareDx is focused on developing high-value healthcare solutions and offers a range of testing services and products for pre- and post-transplant patients. For more details, visit www.CareDx.com.
CareDx, the Transplant Company™, announced the development of AiKidney, an AI-driven tool for assessing the risk of kidney allograft rejection.
This new addition aims to enhance clinical decision-making alongside existing products like AlloSure. AiKidney predicts rejection risk and allograft survival at three, five, and seven years, aligning with CareDx's mission to improve long-term patient outcomes.
Presentations on these innovations will occur at the upcoming Transplant Congress from June 4-8 in Boston.
CareDx, a leader in precision medicine for transplant patients, showcased its innovations at the 2022 American Transplant Congress with over 50 presentations, including the first oral presentation of the OKRA study. The study involved data from over 50 centers, emphasizing the impact of CareDx’s multimodal KidneyCare solutions, including AlloSure and AlloMap. CEO Reg Seeto highlighted the potential of these technologies in improving patient outcomes. The congress runs from June 4-8 in Boston, Massachusetts.
CareDx Expands Transplant Portfolio in Europe
CareDx, Inc. (CDNA) announced the CE marking for its AlloSeq HCT chimerism testing kit and interpretation software, aimed at improving care for hematopoietic cell transplantation (HCT) patients in Europe. This innovative NGS-based test enhances sensitivity in monitoring engraftment compared to traditional methods. CEO Reg Seeto emphasized the company's commitment to delivering high-quality products. Dr. Jean Villard praised the AlloSeq HCT for its superior sensitivity, which could help predict early disease relapse.
CareDx, Inc. has announced the selection of Dr. Berta Sáez-Giménez for the ISHLT Innovation Challenge Award. Her research will utilize AlloSeq cfDNA to monitor treatment for chronic lung allograft dysfunction (CLAD), critical for improving outcomes in lung transplant patients. With a five-year survival rate around 53%, addressing CLAD is vital as it significantly affects mortality rates. CareDx aims to provide early warnings of organ injury through cfDNA testing, thereby enhancing transplant patient care.
CareDx, Inc. (NASDAQ: CDNA) announces updates in its ongoing patent battle with Natera. Natera has withdrawn a patent but has filed two variations against CareDx, which it believes are invalid and not infringed. This development follows a jury trial in March 2022 where CareDx was awarded $44.9 million for Natera's false advertising related to the Prospera test. CareDx maintains that its donor-derived cell-free DNA technology, AlloSure, is specifically designed for transplant patients.
CareDx, Inc. (CDNA) will present its AlloSeq portfolio at the EFI 2022 Conference from May 17-20 in Amsterdam. The AlloSeq solutions, crucial for HLA typing and post-transplant monitoring, highlight the company's leadership in transplant diagnostics. CEO Reg Seeto emphasized CareDx's unique focus on transplant solutions, which serve as vital tools for researchers and clinicians. The symposium on May 18 will discuss advancements in patient care related to transplantation, showcasing significant collaborations in the field.
CareDx, Inc. (CDNA) reported an 18% year-over-year revenue increase to $79.4 million for Q1 2022, driven by strong performance in testing services, which generated $66.4 million. The company showcased scientific leadership at the International Society of Heart and Lung Transplantation with over 25 presentations and secured $44.9 million in damages against Natera for false claims. Despite revenue growth, CareDx recorded a net loss of $19.6 million and a negative EBITDA of $5.6 million. The company reiterated its full-year 2022 revenue guidance of $330 million to $350 million.
FAQ
What is the current stock price of CareDx (CDNA)?
What is the market cap of CareDx (CDNA)?
What does CareDx, Inc. specialize in?
What is AlloSure®?
Which organs do CareDx's products focus on?
Where does CareDx generate most of its revenue?
What are some key products offered by CareDx?
How does CareDx support transplant patients?
What technology does CareDx use in its diagnostics?
Does CareDx collaborate with other healthcare institutions?
What kind of clinical evidence does CareDx generate?
What makes CareDx a leader in transplant diagnostics?
